Next, to investigate the gene expression signature of AML patients with high expression of RBM17, we ranked AML patient samples from the GSE76008 dataset based on RBM17 expression level and defined the top 15% (35 of 221) as RBM17-high cases, and the bottom 15% (35 of 221) as RBM17-low cases. Here, RBM17 is linked to acute myeloid leukemia.